DEA telemedicine controlled substance prescribing compliance is the written policy set that shows how a telehealth practice prescribes schedule II to V controlled substances under DEA's temporary telemedicine rule, 21 CFR 1307.41, whose own text says it is in effect until the end of the day December 31, 2026. It is for telehealth companies, behavioral health groups and other practices with DEA-registered prescribers, and for the pharmacies that serve them. Integral Healthcare Solutions (IHS) drafts the prescriber policies and decision-point procedures for your medical director and counsel to review and approve, and your organization adopts and runs them.
Last reviewed: October 2026.
What is DEA telemedicine controlled substance prescribing compliance?
It is the set of written policies and procedures a prescribing practice uses to show that each controlled substance prescription issued through telemedicine meets DEA's rules. The starting point is the Ryan Haight Act. The extension rule describes the Act as allowing a practitioner to prescribe controlled substances remotely, subject to exceptions, "only after conducting at least one in-person medical evaluation of that patient" (Federal Register document 2025-24123, page opened October 6, 2026). It adds that once that evaluation happens, the Act's specific remote prescribing requirements no longer apply to that practitioner and patient, and the practitioner "must still comply with all other applicable DEA regulations."
DEA and HHS have issued temporary rules that let a DEA-registered practitioner prescribe without that first in-person evaluation when stated conditions are met. 21 CFR 1307.41(b) says "a DEA-registered practitioner is authorized to prescribe schedule II-V controlled substances via telemedicine" to a patient "without having conducted an in-person medical evaluation of the patient" if all of the conditions in paragraph (c) are met. The four conditions follow in IHS's words.
- The prescription is issued for a "legitimate medical purpose" by a practitioner acting in the usual course of professional practice.
- It is issued pursuant to a communication that uses an interactive telecommunications system, as referred to in 42 CFR 410.78(a)(3).
- The practitioner is authorized under their registration to prescribe the basic class of controlled substance involved, or is exempt from registration under 21 U.S.C. 822(d).
- The prescription is consistent with all other requirements of 21 CFR part 1306.
Current status of the DEA telemedicine flexibilities
As of October 6, 2026, the rule IHS found in effect is the fourth temporary extension, which runs through December 31, 2026 (90 FR 61301, published December 31, 2025, effective January 1, 2026). Its abstract says DEA, jointly with HHS, is issuing "a fourth extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026" (Federal Register document 2025-24123, page opened October 6, 2026). The rule text in 21 CFR 1307.41(a) and 42 CFR 12.1(a) says "This section is in effect until the end of the day December 31, 2026."
The rule describes the earlier steps, which are the March 2020 COVID-19 public health emergency exceptions and temporary extensions dated May 10, 2023, October 10, 2023 (through December 31, 2024) and November 19, 2024 (through December 31, 2025). It also describes a January 17, 2025 notice of proposed rulemaking titled "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" (90 FR 6541), which proposed a framework for a special registration for telemedicine and for registration of certain direct-to-consumer platforms.
IHS searched the Federal Register on October 6, 2026 for DEA telemedicine documents published since December 1, 2025. The search returned the fourth extension and one unrelated DEA rule, so IHS found no fifth extension and no final special registration rule. Verify current requirements with DEA, and ask your counsel what applies. IHS does not predict what DEA or HHS will issue.
Who needs a prescriber compliance program, and what triggers it?
Telehealth companies, behavioral health groups and other practices whose DEA-registered practitioners prescribe schedule II to V controlled substances by telemedicine are the buyers, along with pharmacies that serve telehealth prescribers. This page does not say whether any rule applies to your organization, and your counsel decides that. Reasons practices ask for this work, in IHS's reading as of October 2026, include these.
- The current extension has a stated end date, and your policies need a plan for that date.
- If your counsel confirms you rely on the extension, each of the four conditions in 21 CFR 1307.41(c) needs a place in your workflow, such as the visit record and the check of the prescriber's registration.
- A special registration proposal exists (90 FR 6541), and your leaders want to know which documents would change if a final rule replaces the extension.
How does IHS help?
IHS offers process expertise. IHS drafts the program, policies and clinical content for your clinicians to review and approve, and your organization adopts and runs it.
- Gap assessment of your current prescribing policies and visit templates against the text of 21 CFR 1307.41.
- Document and evidence mapping from each of the four conditions to the policy, form or record that shows it.
- Drafting the prescriber policy set and decision-point procedures for both outcomes, for your medical director and counsel to review and approve.
- Mock review of the draft set against the rule text.
- Readiness support while your clinicians revise and adopt the documents.
What you supply: your current prescribing policies and templates, your prescriber and registration list, a description of your telehealth system, and your counsel's view on which rules apply to you. The limit: IHS does not file registrations, does not contact DEA or any state board, does not decide whether a rule applies to your organization, and does not forecast what DEA or HHS will issue. Your organization submits anything to a regulator.
What decision points should the policy set cover?
These are IHS's drafting choices as of October 2026, not requirements of the rule, and your medical director and counsel review and approve each one.
- Scope: which prescribers, schedules and visit types the policy covers.
- The four conditions: where each prescription's record shows each one.
- Registration: how each prescriber's authority for the basic class of controlled substance is confirmed and kept current.
- Calendar: a review date ahead of the end date in the current rule, with a named owner.
- If the flexibilities expire: a documented route for patients who have not had an in-person evaluation, set by your medical director and counsel.
- If a final rule replaces them: a procedure for reading the final text against the policy set and approving revisions.
- Approval and records: who approves, who adopts and where approved versions are kept.
What to have ready
This is IHS's planning list, built from the rule text named above and not from any state's requirements.
- The rule text, 21 CFR 1307.41 and 42 CFR 12.1, as published in Federal Register document 2025-24123.
- Your current controlled substance prescribing policies and visit note templates.
- A list of your prescribers with DEA registration details and the classes each is authorized to prescribe (condition 3).
- A description of your telehealth system and how it meets the reference in 42 CFR 410.78(a)(3) (condition 2).
- The documents that show a legitimate medical purpose and the usual course of professional practice (condition 1).
- The way you check consistency with 21 CFR part 1306, and who owns that check (condition 4).
- The names of your medical director and your counsel.
- Your counsel's written view on which federal and state rules apply to you, if you have one.
- The name of the person who files registrations or submits anything to DEA or a state board.
Printable version of this checklist (PDF)
Bring what you have to the free introductory call.
How does a policy set for both outcomes compare with the alternatives?
Your counsel's advice decides which route fits, and IHS does not recommend one.
| Route | What to know |
|---|---|
| Policy written to the current extension only | IHS's reading, October 2026: it is the shorter document to write, and it is revised in full when the rule changes. |
| Policy with decision points for both outcomes | IHS's reading, October 2026: it carries a documented path for each outcome, so a change calls for review of the matching path in place of a new policy. |
| Waiting for a final rule before writing | IHS makes no prediction about what DEA or HHS will issue or when. Your counsel can advise on whether to wait. |
| Related programs | See telehealth and digital health compliance and ACHC telehealth accreditation, which are different programs, and compliance program development for the written compliance program itself. |
What it costs
The extension rule IHS opened does not state a fee for prescribers. DEA registration fees were not part of this review. Verify current requirements with DEA. IHS scopes each engagement after a free introductory call.
What this is not
- This is not legal advice. IHS is a consulting firm, not a law firm, and IHS gives no opinion on whether a rule applies to your organization. That question belongs to your counsel.
- IHS does not file DEA registrations and does not contact DEA, HHS or any state board. IHS drafts, and your organization adopts, runs and submits.
- This is not a forecast. IHS does not predict whether the flexibilities will end, be extended or be replaced by a final rule.
Frequently asked questions
What is the status of the DEA telemedicine flexibilities for controlled substances?
As of October 6, 2026, the rule IHS found in effect is the fourth temporary extension, and its text says the section is in effect until the end of the day December 31, 2026. IHS searched the Federal Register on October 6, 2026 and found no fifth extension and no final special registration rule.
What can a DEA-registered practitioner do under the extension, and under what conditions?
The rule authorizes a DEA-registered practitioner to prescribe schedule II to V controlled substances via telemedicine without a prior in-person medical evaluation if four conditions in 21 CFR 1307.41(c) are met. Your counsel confirms how this applies to your organization.
What happens when the current extension ends?
The rule text says the section is in effect until the end of the day on its stated end date, and IHS does not predict what DEA or HHS will do next. The rule's background says the Ryan Haight Act allows remote prescribing, subject to exceptions, only after an in-person medical evaluation. Your counsel confirms how that applies to you.
What is the special registration proposal?
It is a January 17, 2025 notice of proposed rulemaking, "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" (90 FR 6541). The extension rule describes it as a proposed framework for a special registration for telemedicine and for registration of certain direct-to-consumer platforms. IHS cites that the proposal exists and does not forecast an outcome.
Who needs a compliance program for telemedicine prescribing?
IHS's reading, October 2026: telehealth companies, behavioral health groups and other practices with DEA-registered prescribers have a reason to write one. Your counsel decides whether any rule applies to your organization.
What decision points should a prescriber policy set cover?
IHS drafts for scope, the four conditions, registration authority, a review date, a path for each outcome, and approval and records. These are IHS's drafting choices, not requirements of the rule. Your medical director and counsel approve each one.
Does the extension change state law?
The rule's four conditions refer to the practitioner's registration and to all other requirements of 21 CFR part 1306. IHS has not read state law for this page, so it does not say what any state requires. Your counsel confirms that.
Why write the policy set for both outcomes?
The rule's end date is fixed in its text, and this page cannot say what follows it. IHS drafts a documented path for each outcome, the flexibilities expiring and a final rule replacing them, so your medical director and counsel can approve both now. This is IHS's drafting approach, not a requirement of the rule.